Thank you, Mr. Chair.
Welcome to all of our witnesses.
I'll be focusing my line of questioning today on screening and early detection using genetic profiling technologies and biomarkers, with a special focus on research. What are we are doing? How we are fairing against other countries, for example, in the OECD? I will open it up to any of our witnesses who are comfortable talking about where we are on research and development, specifically around genetic profiling technology, the use of biomarkers and where we should be. How far are we from a solution, and how are we comparing to other countries?
Anyone, go ahead.